STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ — Hongkong WinHealth Pharma Group
CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti (glycerol phenylbutyrate), in a
territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines